Published in Virology on September 28, 2006
Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One (2008) 2.16
A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology (2007) 1.74
Neutralizing antibodies to HIV-1 induced by immunization. J Exp Med (2013) 1.59
Viral sequence diversity: challenges for AIDS vaccine designs. Expert Rev Vaccines (2008) 1.25
Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice. Virology (2012) 1.16
A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets. PLoS One (2009) 1.13
Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics. Virology (2008) 1.11
The broadly neutralizing anti-human immunodeficiency virus type 1 4E10 monoclonal antibody is better adapted to membrane-bound epitope recognition and blocking than 2F5. J Virol (2008) 1.08
B cells and monocytes from patients with active multiple sclerosis exhibit increased surface expression of both HERV-H Env and HERV-W Env, accompanied by increased seroreactivity. Retrovirology (2009) 1.03
Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine. Virol J (2008) 0.93
Virus-like particles as universal influenza vaccines. Expert Rev Vaccines (2012) 0.93
Nanodisc-incorporated hemagglutinin provides protective immunity against influenza virus infection. J Virol (2010) 0.91
Prime-boost immunization of rabbits with HIV-1 gp120 elicits potent neutralization activity against a primary viral isolate. PLoS One (2013) 0.86
Elicitation of anti-1918 influenza virus immunity early in life prevents morbidity and lower levels of lung infection by 2009 pandemic H1N1 influenza virus in aged mice. J Virol (2011) 0.84
Evaluation of heterologous vaginal SHIV SF162p4 infection following vaccination with a polyvalent Clade B virus-like particle vaccine. AIDS Res Hum Retroviruses (2012) 0.82
Multi-Parameter Exploration of HIV-1 Virus-Like Particles as Neutralizing Antibody Immunogens in Guinea Pigs, Rabbits and Macaques. Virology (2014) 0.82
Induction of humoral and cellular immune responses against the HIV-1 envelope protein using γ-retroviral virus-like particles. Virol J (2011) 0.79
Lentiviral Protein Transfer Vectors Are an Efficient Vaccine Platform and Induce a Strong Antigen-Specific Cytotoxic T Cell Response. J Virol (2015) 0.77
Recent advances on the use of structural biology for the design of novel envelope immunogens of HIV-1. Curr HIV Res (2013) 0.77
Application of virus-like particles (VLP) to NMR characterization of viral membrane protein interactions. J Biomol NMR (2016) 0.77
Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles. Virol J (2011) 0.75
Divergence of primary cognate B- and T-cell proliferative responses to subcutaneous and intravenous immunization with virus-like particles. Viruses (2014) 0.75
Critical role of IL-17RA in immunopathology of influenza infection. J Immunol (2009) 2.51
Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine (2007) 2.31
Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One (2008) 2.16
Seroprevalence following the second wave of Pandemic 2009 H1N1 influenza in Pittsburgh, PA, USA. PLoS One (2010) 2.16
Modeling host responses in ferrets during A/California/07/2009 influenza infection. Virology (2010) 1.93
Impaired immune responses in the lungs of aged mice following influenza infection. Respir Res (2009) 1.67
Properly folded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virus. PLoS One (2010) 1.61
H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine (2008) 1.57
Immune history shapes specificity of pandemic H1N1 influenza antibody responses. J Exp Med (2013) 1.47
Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d. J Virol (2004) 1.38
Impact of glycosylation on the immunogenicity of a DNA-based influenza H5 HA vaccine. Virology (2003) 1.35
Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets. J Virol (2010) 1.31
Induction of heterosubtypic immunity to influenza A virus using a DNA vaccine expressing hemagglutinin-C3d fusion proteins. Vaccine (2003) 1.28
Viral sequence diversity: challenges for AIDS vaccine designs. Expert Rev Vaccines (2008) 1.25
A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine (2008) 1.24
Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigene. Eur J Immunol (2003) 1.12
A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets. Vaccine (2011) 1.12
West Nile virus. Clin Lab Med (2010) 1.10
Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d. J Virol (2003) 1.08
Intranasal antibody gene transfer in mice and ferrets elicits broad protection against pandemic influenza. Sci Transl Med (2013) 1.08
Protection against influenza virus infection by intranasal administration of C3d-fused hemagglutinin. Vaccine (2003) 1.03
HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies. Vaccine (2006) 1.02
Sequential seasonal H1N1 influenza virus infections protect ferrets against novel 2009 H1N1 influenza virus. J Virol (2012) 1.02
Reduction of anti-HIV-1 Gag immune responses during co-immunization: immune interference by the HIV-1 envelope. Curr HIV Res (2007) 1.01
Complement-mediated activation of the adaptive immune responses: role of C3d in linking the innate and adaptive immunity. Immunol Res (2006) 0.99
A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection. J Infect Dis (2012) 0.98
An agent-based model of inflammation and fibrosis following particulate exposure in the lung. Math Biosci (2011) 0.98
Cutting edge: C3d functions as a molecular adjuvant in the absence of CD21/35 expression. J Immunol (2004) 0.95
Virus-like particles: designing an effective AIDS vaccine. Methods (2006) 0.94
Vaccination with DNA plasmids expressing Gn coupled to C3d or alphavirus replicons expressing gn protects mice against Rift Valley fever virus. PLoS Negl Trop Dis (2010) 0.94
DNA epitope vaccine containing complement component C3d enhances anti-amyloid-beta antibody production and polarizes the immune response towards a Th2 phenotype. J Neuroimmunol (2008) 0.94
Effects of aging on influenza virus infection dynamics. J Virol (2014) 0.94
The role of RNA folding free energy in the evolution of the polymerase genes of the influenza A virus. Genome Biol (2009) 0.93
Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine. Virol J (2008) 0.93
C3d enhances immune responses using low doses of DNA expressing the HIV-1 envelope from codon-optimized gene sequences. Curr HIV Res (2005) 0.92
Mouse strain-dependent differences in enhancement of immune responses by C3d. Vaccine (2004) 0.91
DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1. Virology (2004) 0.90
Vaccination of patients with mild and severe asthma with a 2009 pandemic H1N1 influenza virus vaccine. J Allergy Clin Immunol (2010) 0.90
A novel nonhuman primate model for influenza transmission. PLoS One (2013) 0.90
Adjuvants that stimulate TLR3 or NLPR3 pathways enhance the efficiency of influenza virus-like particle vaccines in aged mice. Vaccine (2011) 0.90
Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines. Clin Vaccine Immunol (2011) 0.90
Sequencing, annotation, and characterization of the influenza ferret infectome. J Virol (2012) 0.89
Characterization of a DNA vaccine expressing a human immunodeficiency virus-like particle. Virology (2004) 0.89
Enhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice. Virol J (2010) 0.89
Large scale comparison of innate responses to viral and bacterial pathogens in mouse and macaque. PLoS One (2011) 0.87
Hemagglutinin displayed baculovirus protects against highly pathogenic influenza. Vaccine (2010) 0.87
Complex patterns of human antisera reactivity to novel 2009 H1N1 and historical H1N1 influenza strains. PLoS One (2012) 0.87
Independent but not synergistic enhancement to the immunogenicity of DNA vaccine expressing HIV-1 gp120 glycoprotein by codon optimization and C3d fusion in a mouse model. Vaccine (2004) 0.86
Lentivirus-like particles without reverse transcriptase elicit efficient immune responses. Curr HIV Res (2006) 0.86
Elicitation of anti-1918 influenza virus immunity early in life prevents morbidity and lower levels of lung infection by 2009 pandemic H1N1 influenza virus in aged mice. J Virol (2011) 0.84
Rhesus macaques vaccinated with consensus envelopes elicit partially protective immune responses against SHIV SF162p4 challenge. Virol J (2013) 0.84
A novel outbred mouse model of 2009 pandemic influenza and bacterial co-infection severity. PLoS One (2013) 0.84
A minimum CR2 binding domain of C3d enhances immunity following vaccination. Adv Exp Med Biol (2006) 0.83
Mucosal vaccine vectors: replication-competent versus replication-deficient poxviruses. Curr Pharm Des (2007) 0.83
Evaluation of heterologous vaginal SHIV SF162p4 infection following vaccination with a polyvalent Clade B virus-like particle vaccine. AIDS Res Hum Retroviruses (2012) 0.82
Immunostimulant adjuvant patch enhances humoral and cellular immune responses to DNA immunization. DNA Cell Biol (2008) 0.82
Computationally optimized antigens to overcome influenza viral diversity. Expert Rev Vaccines (2012) 0.81
Cocktail of H5N1 COBRA HA vaccines elicit protective antibodies against H5N1 viruses from multiple clades. Hum Vaccin Immunother (2015) 0.81
Acute murine H5N1 influenza A encephalitis. Brain Pathol (2011) 0.81
Challenges in improving influenza vaccine protection in the elderly. Expert Rev Vaccines (2011) 0.81
Elicitation of immunity to HIV type 1 Gag is determined by Gag structure. AIDS Res Hum Retroviruses (2006) 0.81
Baculovirus-produced influenza virus-like particles in mammalian cells protect mice from lethal influenza challenge. Viral Immunol (2011) 0.80
Developing broadly reactive HIV-1/AIDS vaccines: a review of polyvalent and centralized HIV-1 vaccines. Curr Pharm Des (2007) 0.79
H1N1, but not H3N2, influenza A virus infection protects ferrets from H5N1 encephalitis. J Virol (2013) 0.78
HIV genes diversify in B cells. Curr HIV Res (2008) 0.78
C3d adjuvant activity is reduced by altering residues involved in the electronegative binding of C3d to CR2. Immunol Lett (2010) 0.77
Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies. AIDS Res Hum Retroviruses (2004) 0.77
Multiple residues in the extracellular domains of CCR3 are critical for coreceptor activity. Virology (2004) 0.77
Influenza virus infection elicits protective antibodies and T cells specific for host cell antigens also expressed as tumor-associated antigens: a new view of cancer immunosurveillance. Cancer Immunol Res (2013) 0.77
Challenges and future in vaccines, drug development, and immunomodulatory therapy. Ann Am Thorac Soc (2014) 0.77
Particle-based vaccines for HIV-1 infection. Curr Drug Targets Infect Disord (2003) 0.77
C3d regulates immune checkpoint blockade and enhances antitumor immunity. JCI Insight (2017) 0.77
A novel self-replicating chimeric lentivirus-like particle. J Virol (2011) 0.76
Simian immunodeficiency virus pathogenesis. Curr HIV Res (2009) 0.75
Plasmacytoid dendritic cell depletion leads to an enhanced mononuclear phagocyte response in lungs of mice with lethal influenza virus infection. Comp Immunol Microbiol Infect Dis (2012) 0.75
Absence of fetal transmission of H1N1 despite severe maternal infection. Influenza Other Respir Viruses (2011) 0.75
Antibody neutralization. Curr HIV Res (2007) 0.75
Animal lentiviruses. Editorial. Curr HIV Res (2010) 0.75